analysis of the panel in clinical setting is
needed next to validate this panel of
biomarkers as an effective screening tool
for ovarian cancer.
Friday, June 19, 2009
A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators
This is the Rustin study which was widely debated when presented at ASCO - the one key word in the conclusion (based on the abstract) is: "alone"